Profile: Idera Pharmaceuticals Inc (IDRA.OQ)
22 Jul 2016
Idera Pharmaceuticals, Inc., incorporated on August 24, 2005, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200.
TLR Modulation Technology Platform
Using its chemistry-based platform, the Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. The Company's TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. The Company has also created compounds that are agonists of TLR3, TLR7, TLR8 and TLR9. The Company's TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.
The Company is developing IMO-8400 for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of rare diseases. The Company is developing IMO-8400 for the treatment of certain B-cell lymphomas in which the MYD88 L265P oncogenic mutation is present. The Company is conducting Phase I/II clinical trial of IMO-8400 in Waldenstrom's macroglobulinemia and a Phase I/II trial of IMO-8400 in diffuse large B-cell lymphoma. The Company has completed Phase I clinical trial of IMO-9200 in subjects, as well as preclinical studies of IMO-9200 for a selected autoimmune disease. The Company is developing IMO-2125/IMO-2055 for Intratumoral (combination with checkpoint inhibitors). The Company has completed Phase I/II clinical trial of IMO-2125 in combination with ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 (CTLA4) antibody, in patients with metastatic melanoma.
Program in Rare Diseases
The Company achieved proof of concept for its use of TLRs to inhibit the over-activation of specific TLRs for the treatment of psoriasis and other autoimmune diseases in a randomized, double-blind, placebo-controlled Phase II clinical trial of IMO-8400. The Company is conducting an IMO-8400 development program for dermatomyositis. The Company is also conducting an IMO-8400 development program for Duchenne muscular dystrophy (DMD).
Program in Autoimmune Diseases
The Company's drug candidate in clinical development, IMO-9200, is a synthetic oligonucleotide antagonist of TLR7, TLR8 and TLR9. The Company has completed Phase I clinical trial of administered IMO-9200. The Company is focused on drug development in oncology and rare diseases and it is reviewing various strategic options related to the development of IMO-9200.
Third-generation Antisense (3GA) Technology to Target RNA
The Company is developing 3GA technology to turn off the mRNA associated with disease causing genes. The Company is undertaking an analysis of oncology and rare disease indications for development of drug candidates from its 3GA technology.
The Company competes with Pharmacyclics, Inc., Biogen Idec Inc., Genentech Inc., Hoffmann-La Roche, Chugai Pharmaceutical Co., Ltd., Nimbus Discovery, Inc., Dynavax, InDex Pharmaceuticals AB, Mologen AG, BioLineRx Ltd., Innate Immunotherapeutics Ltd., VentiRx Pharmaceuticals Inc., Telormedix S.A., Gilead Sciences Inc., GlaxoSmithKline plc, Novartis, AstraZeneca plc, Ionis Pharmaceuticals, Inc. and Alnylam.
Idera Pharmaceuticals Inc
167 Sidney St
CAMBRIDGE MA 02139-4237